Posted: 11 Jul 12
Edited: 8 Aug 18
Audits Musculoskeletal
This audit has been designed to ensure that patients prescribed etoricoxib have had their blood pressure measured and that etoricoxib is considered as a potential causal, or exacerbating, factor where hypertension is detected. The patient’s risk of adverse cardiovascular and gastrointestinal events will also be assessed and where appropriate an alternative NSAID may be suggested. All non-steroidal anti-inflammatory drugs should be prescribed at the minimum effective dose for the shortest possible duration.